Clinical efficacy of two forms of intravenous iron--saccharated ferric oxide and cideferron--for iron deficiency anemia.
Over 90% of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the clinical efficacy of these drugs. The purpose of this study was to compare and assess the clinical efficacy of two types of intravenous iron injection, saccharated ferric oxide (SFO) and cideferron (CF). Medical records were obtained for 91 unrelated Japanese anemia patients treated with SFO (n = 37) or CF (n = 54) from May 2005 to May 2010 at Gunma University Hospital. Patients treated with blood transfusion, erythropoietin or oral iron were excluded. Hemoglobin (Hb) values measured on day 0, 7 and 14 were used to assess the efficacy of intravenous irons. A significant increase was observed in the mean Hb value by day 14 of administration in both the CF group and SFO group, and the mean Hb increase due to administration of CF for 7 days was comparable to that of SFO for 14 days. Age and sex did not affect improvement of Hb value. CF is fast acting and highly effective compared with SFO for the treatment of iron deficiency anemia. The use of CF may shorten a therapeutic period for iron deficiency anemia, and CF may be feasible for reducing the hospitalization period.
Department of Pharmacy, Gunma University Hospital, Maebashi, Japan. tkyaraki@gunma-u.ac.jp
T
T
Araki
M
M
Takaai
A
A
Miyazaki
S
S
Ohshima
T
T
Shibamiya
T
T
Nakamura
K
K
Yamamoto
D000368:Aged; D000375:Aging / Q000502:physiology; D000747:Anemia, Hypochromic / Q000188:drug therapy*; D044466:Asian People; D003102:Colloids / Q000008:administration & dosage / Q000627:therapeutic use*; D003287:Contrast Media / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012727:Sex Characteristics
D003102:Colloids; D003287:Contrast Media; D005290:Ferric Compounds; D006454:Hemoglobins; D007501:Iron; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid